Castle Biosciences, Inc.

CSTL Healthcare Diagnostics & Research

Castle Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $344.2 million, up 3.66% from fiscal 2024. In the quarter to June 2026, revenue grew 20.1%, EPS fell 143.8%, free cash flow fell 43.3% and total debt was flat, each against the same quarter a year earlier. Revenue growth for five consecutive years.

31.96 1.84 −5.44%
Market cap
$1.0B
P/E
0.0×
Fwd P/E
−15.2×
Dividend yield
—
F-score
3/9
Altman Z
6.70
Beneish M
−3.49
Dividend safety
n/a

A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.

Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17
Total current assets
361.10 360.15 295.64 292.29 353.74 429.59 116.68 18.13 6.68
Total non-current assets
217.46 171.08 157.71 155.04 108.83 9.73 3.07 4.28 —
Total Assets
578.56 531.24 453.34 447.33 462.57 439.33 119.75 22.41 —
Total current liabilities
68.68 49.39 47.67 36.13 24.89 20.88 15.29 6.74 5.22
Total non-current liabilities
39.01 26.01 14.40 12.05 25.95 2.76 19.34 72.23 —
Total liabilities
107.68 75.40 62.07 48.18 50.83 23.64 34.63 78.97 25.59
Common Equity (Total)
470.87 455.84 391.27 399.15 411.74 415.69 85.11 (56.57) (50.31)
Shareholders Equity (Total)
470.87 455.84 391.27 399.15 411.74 415.69 85.11 (56.57) (15.77)
Total Debt
10.37 10.33 — 13.31 8.08 — 25.12 24.50 20.10

Show all line items

In millions of $ except per-share values · columns are period end dates